A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option

International Journal of Cancer

Volumn 136, Issue 12, 2015, Pages 2940-2948

  Klinghammer, Konrad ^a,b   Raguse, Jan Dirk ^a   Plath, Thomas ^a   Albers, Andreas E ^a   Joehrens, Korinna ^a   Zakarneh, Andre ^c   Brzezicha, Bernadette ^d   Wulf Goldenberg, Annika ^d   Keilholz, Ulrich ^a   Hoffmann, Jens ^d   Fichtner, Iduna ^b,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c St Gertrauden Hospital Berlin   (Germany)

^d Experimental Pharmacology and Oncology EPO GmbH   (Germany)

Author keywords

everolimus; head and neck cancer; HNSCC; mTor; patient avatar; PDX; PI3K; xenograft

Indexed keywords

CARBOPLATIN; CETUXIMAB; DOCETAXEL; EVEROLIMUS; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; METHOTREXATE; ANTINEOPLASTIC AGENT; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DNA SEQUENCE; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RPS6KB1 GENE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ADULT; AGED; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; DEFICIENCY; DRUG EFFECTS; DRUG SCREENING; GENETICS; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS TYPE 16; KNOCKOUT MOUSE; MIDDLE AGED; NONOBESE DIABETIC MOUSE; NUCLEOTIDE SEQUENCE; PAPILLOMAVIRUS INFECTION; PHYSIOLOGY; PROCEDURES; SCID MOUSE; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MALE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84927537860     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29344     Document Type: Article

References (32)

1. Warnakulasuriya S,. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45: 309-16.
2. Langer CJ,. Exploring biomarkers in head and neck cancer. Cancer 2012; 118: 3882-92.
3. Ellis LM, Fidler IJ,. Finding the tumor copycat. Therapy fails, patients don't. Nat Med 2010; 16: 974-5.
4. Braakhuis BJ, van Dongen GA, Bagnay M, et al. Preclinical chemotherapy on human head and neck cancer xenografts grown in athymic nude mice. Head Neck 1989; 11: 511-5.
5. Braakhuis BJ, Schoevers EJ, Heinerman EC, et al. Chemotherapy of human head and neck cancer xenografts with three clinically active drugs: cis-platinum, bleomycin and methotrexate. Br J Cancer 1983; 48: 711-6.
6. Kopetz S, Lemos R, Powis G,. The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res 2012; 18: 5160-2.
7. Bozec A, Peyrade F, Milano G,. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives. Anticancer Agents Med Chem 2013; 13: 389-402.
8. Ito R, Takahashi T, Katano I, et al. Current advances in humanized mouse models. Cell Mol Immunol 2012; 9: 208-14.
9. Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102: 1555-77.
10. Chung CH, Gillison ML,. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009; 15: 6758-62.
11. Zhao M, Rosenbaum E, Carvalho AL, et al. Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. Int J Cancer 2005; 117: 605-10.
12. Simon R,. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 1989; 10: 1-10.
13. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333: 1157-60.
14. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-9.
15. Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003; 100: 8424-9.
16. Meyer DS, Koren S, Leroy C, et al. Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R. Oncogenesis 2013; 2: e74.
17. Keysar SB, Astling DP, Anderson RT, et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol 2013; 7: 776-90.
18. Fichtner I, Rolff J, Soong R, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008; 14: 6456-68.
19. Fichtner I, Becker M, Zeisig R, et al. In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance. Eur J Cancer 2004; 40: 845-51.
20. Haddad TC, Yee D,. Of mice and (wo)men: is this any way to test a new drug? J Clin Oncol 2008; 26: 830-2.
21. Kimple RJ, Harari PM, Torres AD, et al. Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res 2013; 19: 855-64.
22. Sivanand S, Pena-Llopis S, Zhao H, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med 2012; 4: 137ra75.
23. Chen K, Ahmed S, Adeyi O, et al. Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus. PloS One 2012; 7: e39294.
24. Braakhuis BJ, Sneeuwloper G, Snow GB,. The potential of the nude mouse xenograft model for the study of head and neck cancer. Arch Oto-Rhino-Laryngol 1984; 239: 69-79.
25. Voskoglou-Nomikos T, Pater JL, Seymour L,. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003; 9: 4227-39.
26. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84: 1424-31.
27. Molinolo AA, Marsh C, El Dinali M, et al. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. Clin Cancer Res 2012; 18: 2558-68.
28. Aissat N, Le Tourneau C, Ghoul A, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008; 62: 305-13.
29. Faivre S, Dreyer C, Raymond E, et al. Preclinical rational, safety, and preliminary efficacy results of weekly everolimus, carboplatin and paclitaxel as an induction therapy for patients with unresectable locally advanced head and neck squamous cell carcinoma (Capra): a Gercor-Irc Phase I/Ii study. Ann Oncol 2012; 23: 334.
30. Grunwald V, Keilholz U, Boehm A, et al. Temsirolimus is active in refractory squamous cell carcinoma of the head and neck (Scchn) failing platinum-based chemotherapy and cetuximab: efficacy and toxicity data from the phase Ii Temhead study. Ann Oncol 2012; 23: 336-7.
31. Janku F, Wheler JJ, Naing A, et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 2013; 73: 276-84.
32. Polivka J, Jr., Janku F,. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 2013.